Vanda set for best day in over five months as nausea drug shows promise for GLP-1 side effects

Vanda Pharmaceuticals

18/11/2025 15:42

Updates

** Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 17% to $5.15 in early trading

**  Stock set for its biggest percent gain in over five months

** Co says its experimental drug tradipitant significantly reduces nausea and vomiting in people taking the popular weight-loss drug Wegovy, according to results from a new clinical trial

** Study met main goal, 29.3% on tradipitant vomited vs 58.6% on placebo; also reduced severe nausea - VNDA

** Co says late-stage trial planned for 2026

** GLP-1 market exceeds $50 bln globally; tradipitant could boost adherence - VNDA

** Including session's move, stock up ~7% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))